Skip to content
2000
Volume 21, Issue 7
  • ISSN: 1573-4064
  • E-ISSN: 1875-6638

Abstract

Aims

In this current study, a new series of triazolo-triazine derivatives were designed and synthesized as potential anticancer agents.

Methods

The antiproliferative activity of the new compounds was evaluated against four different cancerous cell lines (MDA-MB-231, HCT-116, A549, and HT-29) using an MTT assay. To evaluate the mechanism of action, the ability of the best compound in apoptosis induction and DNA damage was evaluated using the flow cytometry technique and comet assays. Furthermore, molecular docking simulation was used to investigate their interactions with the two targets, VEGFR2 and c-Met kinases.

Results

Results showed that 6-(4-bromophenyl)-3-((4-methoxybenzyl)thio)-[1,2,4]triazolo[4,3-b][1,2,4]triazine () demonstrated the best anti-proliferative activity against the human colorectal carcinoma cells HCT-116 with an IC value of 38.7 ± 1.7 µM. evaluations showed that the triazolo-triazine scaffold, along with the methoxy substitution of compound was involved in creating effective H-bond interactions in the active site of both targets.

Conclusion

Our results showed that compound significantly increased cell death through apoptosis induction and caused a significant increase in genotoxicity. Furthermore, it was found that the tested compound , with a selectivity index of 1.74, possessed selective antiproliferative activity towards the colorectal cancer cell line HCT-116 compared to the normal fibroblast cell line. These findings could be useful in the development of novel VEGFR2/c-Met dual-targeted inhibitors in the future.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/mc/10.2174/0115734064327919240926112444
2024-10-09
2025-10-25

  • From This Site

    /content/journals/mc/10.2174/0115734064327919240926112444
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. TorreL.A. SiegelR.L. WardE.M. JemalA. Global cancer incidence and mortality rates and trends—an update.Cancer Epidemiol. Biomarkers Prev.2016251162710.1158/1055‑9965.EPI‑15‑0578 26667886
     [Google Scholar]
  2. MorganE. ArnoldM. GiniA. LorenzoniV. CabasagC.J. LaversanneM. VignatJ. FerlayJ. MurphyN. BrayF. Global burden of colorectal cancer in 2020 and 2040: Incidence and mortality estimates from GLOBOCAN.Gut202372233834410.1136/gutjnl‑2022‑327736 36604116
     [Google Scholar]
  3. XiY. XuP. Global colorectal cancer burden in 2020 and projections to 2040.Transl. Oncol.2021141010117410.1016/j.tranon.2021.101174 34243011
     [Google Scholar]
  4. XiaoZ. Morris-NatschkeS.L. LeeK.H. Strategies for the optimization of natural leads to anticancer drugs or drug candidates.Med. Res. Rev.2016361329110.1002/med.21377 26359649
     [Google Scholar]
  5. van der ZandenS.Y. QiaoX. NeefjesJ. New insights into the activities and toxicities of the old anticancer drug doxorubicin.FEBS J.2021288216095611110.1111/febs.15583 33022843
     [Google Scholar]
  6. XieJ. ZhangX. MengD. LiY. DengP. Identification of potentially high drug-like VEGFR2/c-Met dual-target type II kinase inhibitors with symmetric skeletons based on structural screening.J. Biomol. Struct. Dyn.20244231249126710.1080/07391102.2023.2199082 37042992
     [Google Scholar]
  7. RusinovV.L. CharushinV.N. ChupakhinO.N. Biologically active azolo-1,2,4-triazines and azolopyrimidines.Russ. Chem. Bull.201867457359910.1007/s11172‑018‑2113‑8
     [Google Scholar]
  8. BuchananS.G. HendleJ. LeeP.S. SmithC.R. BounaudP.Y. JessenK.A. TangC.M. HuserN.H. FelceJ.D. FroningK.J. PetermanM.C. AubolB.E. GessertS.F. SauderJ.M. SchwinnK.D. RussellM. RooneyI.A. AdamsJ. LeonB.C. DoT.H. BlaneyJ.M. SprengelerP.A. ThompsonD.A. SmythL. PelletierL.A. AtwellS. HolmeK. WassermanS.R. EmtageS. BurleyS.K. ReichS.H. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo.Mol. Cancer Ther.20098123181319010.1158/1535‑7163.MCT‑09‑0477 19934279
     [Google Scholar]
  9. HeinrichM.C. JonesR.L. von MehrenM. SchöffskiP. SerranoC. KangY.K. CassierP.A. MirO. EskensF. TapW.D. RutkowskiP. ChawlaS.P. TrentJ. TugnaitM. EvansE.K. LauzT. ZhouT. RocheM. WolfB.B. BauerS. GeorgeS. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): A multicentre, open-label, phase 1 trial.Lancet Oncol.202021793594610.1016/S1470‑2045(20)30269‑2 32615108
     [Google Scholar]
  10. BhideR.S. CaiZ.W. ZhangY.Z. QianL. WeiD. BarbosaS. LombardoL.J. BorzilleriR.M. ZhengX. WuL.I. BarrishJ.C. KimS.H. LeavittK. MathurA. LeithL. ChaoS. WautletB. MortilloS. JeyaseelanR.Sr KukralD. HuntJ.T. KamathA. FuraA. VyasV. MaratheP. D’ArienzoC. DerbinG. FargnoliJ. Discovery and preclinical studies of (R)-1-(4-(4-Fluoro-2-methyl-1 H -indol-5-yloxy)-5- methylpyrrolo[2,1- f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.J. Med. Chem.20064972143214610.1021/jm051106d 16570908
     [Google Scholar]
  11. CuiJ.J. ShenH. Tran-DubéM. NambuM. McTigueM. GrodskyN. RyanK. YamazakiS. AguirreS. ParkerM. LiQ. ZouH. ChristensenJ. Lessons from (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in rats.J. Med. Chem.201356176651666510.1021/jm400926x 23944843
     [Google Scholar]
  12. DadashpourS. KüçükkılınçT.T. AyazgökB. HosseinimehrS.J. ChippindaleA.M. ForoumadiA. IrannejadH. Discovery of novel 1,2,4-triazolo-1,2,4-triazines with thiomethylpyridine hinge binders as potent c-Met kinase inhibitors.Future Med. Chem.201911101119113610.4155/fmc‑2018‑0412 31280674
     [Google Scholar]
  13. KhatirZ.Z. Di SottoA. PercaccioE. Tuylu KucukkilincT. ErcanA. ChippindaleA.M. ValipourM. IrannejadH. 4‐3‐[(Pyridin‐4‐ylmethyl)amino]‐[1,2,4]triazolo[4,3‐ b][1,2,4]triazin‐6‐ylphenol: An improved anticancer agent in hepatocellular carcinoma and a selective MDR1/MRP modulator.Arch. Pharm.20243576230070410.1002/ardp.202300704 38442326
     [Google Scholar]
  14. GuoY. PengX. JiY. ZhangY. DingJ. ZhanZ. AiJ. DuanW. Synthesis of triazolotriazine derivatives as c-Met inhibitors.Mol. Divers.202125283984610.1007/s11030‑020‑10067‑5 32157572
     [Google Scholar]
  15. ChenF. WangY. AiJ. ZhanZ. LvY. LiangZ. LuoC. MeiD. GengM. DuanW. O-linked triazolotriazines: Potent and selective c-Met inhibitors.ChemMedChem2012771276128510.1002/cmdc.201200145 22539497
     [Google Scholar]
  16. GrozavA. GăinăL. PileczkiV. CrisanO. Silaghi-DumitrescuL. TherrienB. ZahariaV. Berindan-NeagoeI. The synthesis and antiproliferative activities of new arylidene-hydrazinyl-thiazole derivatives.Int. J. Mol. Sci.20141512220592207210.3390/ijms151222059 25470024
     [Google Scholar]
  17. LvP.C. LiD.D. LiQ.S. LuX. XiaoZ.P. ZhuH.L. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents.Bioorg. Med. Chem. Lett.201121185374537710.1016/j.bmcl.2011.07.010 21802290
     [Google Scholar]
  18. dos Santos SilvaT.D. BomfimL.M. da Cruz RodriguesA.C.B. DiasR.B. SalesC.B.S. RochaC.A.G. SoaresM.B.P. BezerraD.P. de Oliveira CardosoM.V. LeiteA.C.L. MilitãoG.C.G. Anti-liver cancer activity in vitro and in vivo induced by 2-pyridyl 2,3-thiazole derivatives.Toxicol. Appl. Pharmacol.201732921222310.1016/j.taap.2017.06.003 28610992
     [Google Scholar]
  19. SharmaP. Srinivasa ReddyT. ThummuriD. SenwarK.R. Praveen KumarN. NaiduV.G.M. BhargavaS.K. ShankaraiahN. Synthesis and biological evaluation of new benzimidazole-thiazolidinedione hybrids as potential cytotoxic and apoptosis inducing agents.Eur. J. Med. Chem.201612460862110.1016/j.ejmech.2016.08.029 27614408
     [Google Scholar]
  20. GomhaS.M. AbdelazizM.R. KhederN.A. Abdel-azizH.M. AlteraryS. MabkhotY.N. A facile access and evaluation of some novel thiazole and 1,3,4-thiadiazole derivatives incorporating thiazole moiety as potent anticancer agents.Chem. Cent. J.201711110510.1186/s13065‑017‑0335‑8 29086869
     [Google Scholar]
  21. WolfJ. SetoT. HanJ.Y. ReguartN. GaronE.B. GroenH.J.M. TanD.S.W. HidaT. de JongeM. OrlovS.V. SmitE.F. SouquetP.J. VansteenkisteJ. HochmairM. FelipE. NishioM. ThomasM. OhashiK. ToyozawaR. OverbeckT.R. de MarinisF. KimT.M. LaackE. RobevaA. Le MouhaerS. Waldron-LynchM. SankaranB. BalbinO.A. CuiX. GiovanniniM. AkimovM. HeistR.S. Capmatinib in MET exon 14–mutated or MET-amplified non–small-cell lung cancer.N. Engl. J. Med.20203831094495710.1056/NEJMoa2002787 32877583
     [Google Scholar]
  22. ZhanZ. PengX. LiuQ. ChenF. JiY. YaoS. XiY. LinY. ChenT. XuY. AiJ. GengM. DuanW. Discovery of 6-(difluoro(6-(4-fluorophenyl)-[1,2,4]triazolo[4,3- b][1,2,4]triazin-3-yl)methyl)quinoline as a highly potent and selective c-Met inhibitor.Eur. J. Med. Chem.201611623925110.1016/j.ejmech.2016.03.076 27061987
     [Google Scholar]
  23. ValipourM. NaderiN. HeidarliE. ShakiF. MotafeghiF. Talebpour AmiriF. EmamiS. IrannejadH. Design, synthesis and biological evaluation of naphthalene-derived (arylalkyl)azoles containing heterocyclic linkers as new anticonvulsants: A comprehensive in silico, in vitro, and in vivo study.Eur. J. Pharm. Sci.202116610597410.1016/j.ejps.2021.105974 34390829
     [Google Scholar]
  24. TuttyM.A. VellaG. VennemannA. WiemannM. Prina-MelloA. Evaluating nanobiomaterial-induced DNA strand breaks using the alkaline comet assay.Drug Deliv. Transl. Res.20221292243225810.1007/s13346‑022‑01178‑7 35612707
     [Google Scholar]
  25. Al-MusawiS. HadiA.J. HadiS.J. HindiN.K.K. Preparation and characterization of folated chitosan-magnetic nanocarrier for 5-fluorouracil drug delivery and studying its effect in bladder cancer therapy.J. Glob. Pharma Technol.201911628637
     [Google Scholar]
  26. NjiojobC.N. RhinehartJ.L. BozellJ.J. LongB.K. Synthesis of enantiomerically pure lignin dimer models for catalytic selectivity studies.J. Org. Chem.20158031771178010.1021/jo502685k 25584871
     [Google Scholar]
  27. MarchandP. AntoineM. GerlachM. GüntherE. SchusterT. CzechM. SeipeltI. A convenient synthesis of novel 2, 8-disubstituted pyrido [3, 4-b] pyrazines possessing biological activity.Synthesis2012441698210.1055/s‑0031‑1289613
     [Google Scholar]
  28. DadashpourS. KüçükkılınçT.T. ErcanA. HosseinimehrS.J. NaderiN. IrannejadH. Synthesis and anticancer activity of benzimidazole/benzoxazole substituted triazolotriazines in hepatocellular carcinoma.Anti-Cancer. Agents Med. Chem.20191921202129
     [Google Scholar]
  29. CollinsA.R. The comet assay for DNA damage and repair: Principles, applications, and limitations.Mol. Biotechnol.200426324926110.1385/MB:26:3:249 15004294
     [Google Scholar]
  30. AghajanshakeriS. SalmanmahinyA. AghajanshakeriS. BabaeiA. AlishahiF. BabayaniE. ShokrzadehM. Modulatory effect of amifostine (WR-1065) against genotoxicity and oxidative stress induced by methotrexate in human umbilical vein endothelial cells (HUVECs).Toxicol. Mech. Methods202333975576510.1080/15376516.2023.2238069 37537746
     [Google Scholar]
  31. AghajanshakeriS. AtaeeR. KaramiM. AghajanshakeriS. ShokrzadehM. Cytomodulatory characteristics of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) against cypermethrin on skin fibroblast cells (HFF-1).Toxicology202349915365510.1016/j.tox.2023.153655 37871686
     [Google Scholar]
/content/journals/mc/10.2174/0115734064327919240926112444
Loading
Design and Development of [1,2,4]Triazolo[4,3-b][1,2,4]triazines as Potential Anticancer Agents with Genotoxicity and Apoptotic Activity
Med. Chem. 21, 680 (2025); https://doi.org/10.2174/0115734064327919240926112444
/content/journals/mc/10.2174/0115734064327919240926112444
/content/journals/mc/10.2174/0115734064327919240926112444
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): Anticancer; apoptosis; c-Met; DNA damage; triazolo-triazine; VEGFR2

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test